Aeterna Zentaris (AEZS) Competitors $3.41 0.00 (0.00%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock AEZS vs. TENX, CARA, FBLG, CVKD, CYTH, BCAB, OVID, ALXO, NNVC, and CALCShould you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Tenax Therapeutics (TENX), Cara Therapeutics (CARA), FibroBiologics (FBLG), Cadrenal Therapeutics (CVKD), Cyclo Therapeutics (CYTH), BioAtla (BCAB), Ovid Therapeutics (OVID), ALX Oncology (ALXO), NanoViricides (NNVC), and CalciMedica (CALC). These companies are all part of the "pharmaceutical products" industry. Aeterna Zentaris vs. Its Competitors Tenax Therapeutics Cara Therapeutics FibroBiologics Cadrenal Therapeutics Cyclo Therapeutics BioAtla Ovid Therapeutics ALX Oncology NanoViricides CalciMedica Tenax Therapeutics (NASDAQ:TENX) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends. Which has more volatility and risk, TENX or AEZS? Tenax Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Is TENX or AEZS more profitable? Tenax Therapeutics has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -760.32%. Tenax Therapeutics' return on equity of -31.51% beat Aeterna Zentaris' return on equity.Company Net Margins Return on Equity Return on Assets Tenax TherapeuticsN/A -31.51% -30.35% Aeterna Zentaris -760.32%-83.45%-45.76% Does the media prefer TENX or AEZS? In the previous week, Tenax Therapeutics' average media sentiment score of 0.00 equaled Aeterna Zentaris'average media sentiment score. Company Overall Sentiment Tenax Therapeutics Neutral Aeterna Zentaris Neutral Which has stronger earnings & valuation, TENX or AEZS? Aeterna Zentaris has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenax TherapeuticsN/AN/A-$17.60M-$2.48-2.40Aeterna Zentaris$2.37M2.58-$16.55M-$14.86-0.23 Do institutionals & insiders believe in TENX or AEZS? 1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 0.7% of Aeterna Zentaris shares are owned by institutional investors. 3.7% of Tenax Therapeutics shares are owned by insiders. Comparatively, 0.1% of Aeterna Zentaris shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate TENX or AEZS? Tenax Therapeutics currently has a consensus target price of $17.50, indicating a potential upside of 193.62%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Tenax Therapeutics is more favorable than Aeterna Zentaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Aeterna Zentaris 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryTenax Therapeutics beats Aeterna Zentaris on 11 of the 14 factors compared between the two stocks. Get Aeterna Zentaris News Delivered to You Automatically Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AEZS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AEZS vs. The Competition Export to ExcelMetricAeterna ZentarisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.11M$812.96M$5.56B$9.05BDividend YieldN/A4.84%5.24%3.99%P/E Ratio-0.231.1519.9620.26Price / Sales2.58230.41419.56119.26Price / CashN/A23.4426.2128.59Price / Book0.236.328.035.65Net Income-$16.55M-$27.99M$3.18B$249.15M7 Day Performance2.10%2.10%2.93%3.28%1 Month Performance-8.33%9.39%1.72%3.95%1 Year Performance-28.21%11.51%34.39%20.98% Aeterna Zentaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AEZSAeterna ZentarisN/A$3.41flatN/A-28.2%$6.11M$2.37M-0.2320TENXTenax Therapeutics1.265 of 5 stars$5.87+0.3%$17.50+198.4%+89.8%$24.34MN/A-2.369CARACara Therapeutics0.3356 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580News CoverageGap DownHigh Trading VolumeFBLGFibroBiologics2.2861 of 5 stars$0.63+1.1%$13.00+1,966.8%-87.0%$24.22MN/A-3.0110Gap UpCVKDCadrenal Therapeutics2.8547 of 5 stars$12.05+0.0%$32.00+165.5%N/A$23.75MN/A-1.304Positive NewsGap UpCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809BCABBioAtla2.7324 of 5 stars$0.40+1.0%$5.00+1,150.0%-71.2%$23.60M$11M-0.3360News CoverageGap DownOVIDOvid Therapeutics4.2249 of 5 stars$0.33-0.6%$3.13+852.7%-53.9%$23.32M$570K-0.9460ALXOALX Oncology2.6469 of 5 stars$0.43+3.6%$3.30+667.4%-91.4%$22.96MN/A-0.1740Positive NewsGap UpNNVCNanoViricides1.0876 of 5 stars$1.40flatN/A-20.0%$22.50MN/A-1.9420Gap DownCALCCalciMedica3.0734 of 5 stars$1.71+6.8%$18.00+953.2%-61.8%$22.17MN/A-1.0230 Related Companies and Tools Related Companies TENX Alternatives CARA Alternatives FBLG Alternatives CVKD Alternatives CYTH Alternatives BCAB Alternatives OVID Alternatives ALXO Alternatives NNVC Alternatives CALC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AEZS) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredGold buying hits 4-year highThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
